Exousia Pro Files Reg A.
Exousia Pro (OTCPINK:MAJI), a clinical-stage biotech company, has filed a Regulation A offering to raise up to $4.985 million for various business initiatives. The company plans to allocate the funds across several key areas, with the largest portion ($2 million) dedicated to Investigational New Drug (IND) trials for Glioblastoma treatment.
The funding will also support new product development from mushroom exosomes ($1 million), potential acquisitions ($1.5 million), lab equipment ($250,000), marketing ($150,000), and working capital ($85,000). The company emphasizes a strategic approach to raising capital, planning to secure funds as needed to avoid excessive shareholder dilution.
Exousia Pro (OTCPINK:MAJI), un'azienda biotech in fase clinica, ha presentato un'offerta ai sensi del Regolamento A per raccogliere fino a 4,985 milioni di dollari destinati a diverse iniziative aziendali. La società intende destinare i fondi a vari settori chiave, riservando la quota maggiore (2 milioni di dollari) alle sperimentazioni per un nuovo farmaco (IND) per il trattamento del Glioblastoma.
I finanziamenti supporteranno anche lo sviluppo di nuovi prodotti a base di esosomi di funghi (1 milione di dollari), potenziali acquisizioni (1,5 milioni di dollari), attrezzature di laboratorio (250.000 dollari), attività di marketing (150.000 dollari) e capitale circolante (85.000 dollari). L’azienda sottolinea un approccio strategico alla raccolta fondi, pianificando di ottenere finanziamenti solo quando necessario per evitare un’eccessiva diluizione degli azionisti.
Exousia Pro (OTCPINK:MAJI), una empresa biotecnológica en fase clínica, ha presentado una oferta bajo la Regulación A para recaudar hasta 4.985 millones de dólares destinados a diversas iniciativas comerciales. La compañía planea asignar los fondos a varias áreas clave, destinando la mayor parte (2 millones de dólares) a ensayos de Nuevos Fármacos en Investigación (IND) para el tratamiento del Glioblastoma.
La financiación también apoyará el desarrollo de nuevos productos basados en exosomas de hongos (1 millón de dólares), adquisiciones potenciales (1,5 millones de dólares), equipamiento de laboratorio (250.000 dólares), marketing (150.000 dólares) y capital de trabajo (85.000 dólares). La empresa destaca un enfoque estratégico para la captación de capital, planeando obtener fondos según sea necesario para evitar una dilución excesiva de los accionistas.
Exousia Pro (OTCPINK:MAJI)는 임상 단계의 바이오테크 기업으로, 다양한 사업 이니셔티브를 위해 최대 498만 5천 달러를 조달하기 위한 규정 A(Regulation A) 공모를 신청했습니다. 회사는 자금을 여러 핵심 분야에 배분할 계획이며, 가장 큰 부분인 200만 달러는 교모세포종 치료를 위한 신약 임상시험(IND)에 할당됩니다.
이 자금은 버섯 엑소좀을 이용한 신제품 개발(100만 달러), 잠재적 인수(150만 달러), 실험실 장비(25만 달러), 마케팅(15만 달러), 그리고 운전자본(8만 5천 달러)에도 사용될 예정입니다. 회사는 과도한 주주 희석을 피하기 위해 필요에 따라 자금을 확보하는 전략적 자본 조달 방식을 강조합니다.
Exousia Pro (OTCPINK:MAJI), une société biotechnologique en phase clinique, a déposé une offre selon le Règlement A visant à lever jusqu'à 4,985 millions de dollars pour diverses initiatives commerciales. L'entreprise prévoit d'allouer les fonds à plusieurs domaines clés, la plus grande part (2 millions de dollars) étant destinée aux essais cliniques d'un nouveau médicament (IND) pour le traitement du glioblastome.
Le financement soutiendra également le développement de nouveaux produits à base d'exosomes de champignons (1 million de dollars), des acquisitions potentielles (1,5 million de dollars), du matériel de laboratoire (250 000 dollars), le marketing (150 000 dollars) et le fonds de roulement (85 000 dollars). La société souligne une approche stratégique de la levée de fonds, prévoyant de sécuriser les financements au fur et à mesure des besoins afin d'éviter une dilution excessive des actionnaires.
Exousia Pro (OTCPINK:MAJI), ein Biotech-Unternehmen in der klinischen Phase, hat ein Angebot gemäß Regulation A eingereicht, um bis zu 4,985 Millionen US-Dollar für verschiedene Geschäftsinitiativen zu sammeln. Das Unternehmen plant, die Mittel auf mehrere Schlüsselbereiche zu verteilen, wobei der größte Anteil (2 Millionen US-Dollar) für klinische Studien eines neuen Arzneimittels (IND) zur Behandlung von Glioblastom vorgesehen ist.
Die Finanzierung unterstützt zudem die Entwicklung neuer Produkte aus Pilz-Exosomen (1 Million US-Dollar), potenzielle Übernahmen (1,5 Millionen US-Dollar), Laborausstattung (250.000 US-Dollar), Marketing (150.000 US-Dollar) und Betriebskapital (85.000 US-Dollar). Das Unternehmen betont einen strategischen Ansatz bei der Kapitalbeschaffung und plant, Mittel bedarfsgerecht zu sichern, um eine übermäßige Verwässerung der Aktionäre zu vermeiden.
- None.
- None.
ORLANDO, FLORIDA / ACCESS Newswire / June 25, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), Exousia Pro, Inc., a clinical-stage biotech company utilizing exosomes in therapies helpful in the treatment of cancer and other diseases, has filed a Reg A (File # 024-12629).
Exousia Pro has filed a Reg A to raise money for the following:
Use of Proceeds for Assumed Percentage of Company Offered Shares Sold in This Offering | ||||||||||||||||
Investigational New Drug trials | 500,000 | 1,000,000 | 1,500,000 | 2,000,000 | ||||||||||||
New Product Development | 250,000 | 500,000 | 750,000 | 1,000,000 | ||||||||||||
Acquisition | 250,000 | 500,000 | 1,000,000 | 1,500,000 | ||||||||||||
Lab Equipment | 100,000 | 150,000 | 200,000 | 250,000 | ||||||||||||
Marketing | 50,000 | 75,000 | 100,000 | 150,000 | ||||||||||||
Working Capital | 85,000 | 260,000 | 200,000 | 85,000 | ||||||||||||
Total | $ | 1,235,000 | $ | 2,485,000 | $ | 3,735,000 | $ | 4,985,000 | ||||||||
We plan to use the bulk of the money to begin Glioblastoma IND trials, while we work on partnering with a large pharmaceutical company. Our Scientific Advisory Board ("SAB") has identified the first new product we plan to bring to market from mushroom exosomes. We have allocated funds for future acquisitions, which will be used to cover legal and accounting costs. As we continue to evolve, we will need to add or update our existing lab equipment. The marketing money will be used to market our various exosome products. We are assembling a marketing team with decades of experience in television, PR, and IR to effectively market the Company and its products. The Company operates very lean, and with sales projected this month and beyond, we allocated the smallest amount to working capital.
Matt Dwyer, our President, stated, "Exousia Pro can grow with funding; we can expand our studies, which could lead to further IND trials, but we do not have to do all these things at once and dilute the hell out of the Company's shareholders. As we plan future studies, we will determine our costs and allocate funds accordingly, allowing us to raise money as needed. We hope to be a model other companies will follow and show how a Reg A can be beneficial without being detrimental to the shareholders."
Exousia Pro intends to conduct its Reg A offering in a drastically different manner than the typical OTC company. Instead, the Company plans to stay true to the offering price of the Reg A, that is, no discounts, as it raises capital and executes its ambitious business plan, with the support of its investors. The Company has established an anticipated schedule for the use of funding, and it will raise funds as needed, in accordance with this schedule.
About Us
Exousia Pro (formerly Marijuana, Inc.) is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused on oncology. The company's patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications, from dermatology to dentistry. The company's proprietary loading technology can infuse a range of molecules from drugs to DNA.
For more information, please visit: www.exousiapro.com
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Exousia Pro, Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the parties' future level of business. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Exousia Pro, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Exousia Pro, Inc.
www.Exousiapro.com
Twitter: @Exousia_Pro
Investor Relations
ir@exousiapro.com
SOURCE: Marijuana Inc.
View the original press release on ACCESS Newswire
